Recorded October 8, 2015

Sponsored by

Webinar Description:

We will provide an introduction to the Simoa technology--which is capable of provided a 1000-fold improvement in sensitivity to proteins over conventional assays--and describe how it can be used to detect multiple proteins at the single molecule level. We will describe the use of single molecule arrays (Simoa) for the multiplex detection of proteins at very low concentrations and discuss how to use a Simoa homebrew assay.

We will present how homebrew Simoa assays utilizing novel antibodies against functional forms of the chemokine CXCL10 are allowing us to study the in vivo processing of this crucial immune mediator. Chemokines play an essential role in cell migration. Regulation of their activity is particularly important during immune responses in order to recruit immune cells to lymphoid organs or target them towards injured tissues. Post-translational modification of chemokines has been shown to regulate their chemotactic activity, however in vivo evidence, until now, had remained limited to observational studies and experimental mouse models.

Learning Objectives:

  • Understanding the basics of Simoa technology and Simoa HD-1 Analyzer
  • Background on the use of a single or multiplex Simoa homebrew kit
  • Understanding of biology of post-translational modifications of CXCL10
  • Examples from chronic infectious disease


Darragh DuffyDarragh Duffy, Ph.D.

Immunobiology of Dendritic Cells, Inserm U818

Département d'Immunologie
Institut Pasteur


Throughout my career I have been interested in how a better understanding of fundamental immunology can be applied to novel solutions for improving human health. For this reason I undertook a PhD in immunology followed by post-doctoral research positions working on novel vaccine candidates for HIV and TB. As my career has progressed I have moved closer to translational research that can deliver research findings to the clinic. In 2012 I joined the team of Matthew Albert at Institut Pasteur where I am leading biomarker discovery projects in chronic infection. In particular, we are focusing on how post-translationally modified chemokines can be used to stratify patient populations, and with this in mind we have been developing and applying novel Simoa assays.

David DuffyDavid Duffy, Ph.D.

Vice President, Research and Chief Technology Officer



Dr. Duffy joined Quanterix in 2007 and leads the team of scientists developing its single molecule detection technology. Dr. Duffy was previously at Surface Logix, where he was the Director of Pharmacomer Technology. There he oversaw the development of a novel chemical technology for optimizing the PK/PD of small molecules that resulted in two drug candidates currently in Phase II clinical trials. Prior to that, Dr. Duffy was at Gamera Biosciences where he was a co-inventor of a centrifugal microfluidic device called the LabCD that was acquired and commercialized by Tecan. Dr. Duffy is an inventor on 12 U.S. patents and has more than 20 publications in the fields of surface chemistry, microfluidics, and bioanalysis. Dr. Duffy was a postdoctoral research fellow in the Department of Chemistry and Chemical Biology at Harvard University. He was the first Sir Alan Wilson Research Fellow of Emmanuel College, University of Cambridge. Dr. Duffy obtained his Ph.D. in physical chemistry from the Department of Chemistry at the University of Cambridge, and his B.A. and M.A. degrees in Natural Sciences from Selwyn College, University of Cambridge.